Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors
返回论文页
|更新时间:2023-12-22
|
Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors
DONG Lin,SHU Yishuo,DONG Zhonghua,et al.Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors[J].ZHONGGUO YAOFANG,2023,34(24):3025-3029.
DONG Lin,SHU Yishuo,DONG Zhonghua,et al.Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors[J].ZHONGGUO YAOFANG,2023,34(24):3025-3029. DOI: 10.6039/j.issn.1001-0408.2023.24.12.
Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors
To analyze the dose-adjusted concentrations of Posaconazole oral suspension in patients undergoing hematopoietic stem cell transplantation (HSCT) and their influential factors.
METHODS
2
Data were collected from hospitalized HSCT patients admitted to the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital) from January 2021 to April 2023 who took Posaconazole oral suspension for the prevention of invasive fungal disease (IFD) and received blood concentration of posaconazole. The rate of concentration attainment and clinical failure rate of posaconazole for the prevention of IFD were evaluated, and one-way and multiple linear regression analyses were performed for the influential factors of dose-adjusted concentrations (
C
0
/
D
) of posaconazole.
RESULTS
2
A total of 44 patients were enrolled; the mean
C
0
of posaconazole in patients was (0.99±0.94) µg/mL, and 20 patients had a
C
0
≥0.7 μg/mL, with a concentration attainment rate of 45.45% for the prevention of IFD; 13 cases were clinical failures, with a clinical failure rate of 29.55%. Of 24 patients who did not achieve
C
0
/
D
of posaconazole for IFD prophylaxis, one patient was a clinical failure despite timely dose adjustment of posaconazole in seven patients; seven of the thirteen patients who did not undergo dose adjustment were clinical failures; and the remaining four patients were switched to other antifungal agents. The results of univariate analysis showed that gender, body mass index (BMI), renal function, combined use of sodium phenytoin, omeprazole and metoclopramide had a significant effect on the
C
0
/
D
of posaconazole (
P
<0.05); the results of multivariate linear regression analysis showed that gender, BMI and combined use of sodium phenytoin were the independent factors affecting the
C
0
/
D
of posaconazole (
P
<0.05).
CONCLUSIONS
2
Significant individual differences are reflected in the blood concentration of Posaconazole oral suspension; gender, BMI and combined use of sodium phenytoin are independent factors affecting the
C
0
/
D
of posaconazole.
关键词
泊沙康唑剂量校正浓度影响因素造血干细胞移植治疗药物监测
Keywords
dose-adjusted concentrationinfluential factorhematopoietic stem cell transplantationtherapeutic drug monitoring
references
MARKS D I,LIU Q F,SLAVIN M. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation[J]. Expert Rev Anti Infect Ther, 2017, 15(5):493-502.
PENG Y N,BIAN Z L,CAO W J,et al. Efficacy and safety study of posaconazole and voriconazole for the prevention of invasive fungal infections after allogeneic hematopoietic stem cell transplantation[J]. J Pract Med,2023,39(6):742-746.
CHEN L,KREKELS E H J,VERWEIJ P E,et al. Pharmacokinetics and pharmacodynamics of posaconazole[J]. Drugs,2020,80(7):671-695.
EIDEN C,MENIANE J C,PEYRIÈRE H,et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis:influence of food intake[J]. Eur J Clin Microbiol Infect Dis,2012,31(2):161-167.
JIN L,XU W B,YE C J,et al. Prophylactic antifungal effect of posaconazole on patients with hematological malignant tumor undergoing chemotherapy[J]. J Shanghai Jiao Tong Univ Med Sci,2022,42(6):792-796.
ZHANG F Y,ZHANG R X,SONG X W,et al. Research progress of influencing factors for plasma concentration of posaconazole[J]. Chin J Hosp Pharm,2021,41(9):971-976.
QU R C,YU J,WANG Z Y,et al. Effect of posaconazole combined with proton pump inhibitors on blood concentrations and invasive fungal infection in patients with malignant hematological disorders[J]. China Pharm,2023,34(10):1237-1241.
VAN DER ELST K C,BROUWERS C H,VAN DEN HEUVEL E R,et al. Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease[J]. Ther Drug Monit,2015,37(6):766-771.
JOHN J,LOO A,MAZUR S,et al. Therapeutic drug monitoring of systemic antifungal agents:a pragmatic approach for adult and pediatric patients[J]. Expert Opin Drug Metab Toxicol,2019,15(11):881-895.
DOLTON M J,BRÜGGEMANN R J,BURGER D M,et al. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis[J]. Antimicrob Agents Chemother,2014,58(11):6879-6885.
SHU Y S,SHI Y P,YANG Y L,et al. Progress of triazole antifungal agent posaconazole in individualized therapy[J]. J Clin Pharm Ther,2022,47(12):1966-1981.
National Pharmacopoeia Commission. Chinese pharmacopoeia:part Ⅳ[M]. 2020 Edition. Beijing:China Medical Science Press,2020:466-472.
DE PAUW B,WALSH T J,DONNELLY J P,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC/MSG)Consensus Group[J]. Clin Infect Dis,2008,46(12):1813-1821.
SEGAL B H,HERBRECHT R,STEVENS D A,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases:Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria[J]. Clin Infect Dis,2008,47(5):674-683.
SHEN Y,HUANG X J,WANG J X,et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China:a multicenter,randomized,open-label study[J]. Int J Clin Pharmacol Ther,2013,51(9):738-745.
CORNELY O A,MAERTENS J,WINSTON D J,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia[J]. N Engl J Med,2007,356(4):348-359.
DESPLANQUES P Y,BURLACU R,POINSIGNON V,et al. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia[J]. Med Mal Infect,2014,44(4):174-179.
JIA M M,ZHANG Q W,QIN Z F,et al. Deciphering the relationship between the trough concentration of posaco-nazole and its efficacy and safety in Chinese patients with hematological disorders[J]. Front Pharmacol,2020,11:575463.
MÄRTSON A G,VERINGA A,BAKKER M,et al. Posaconazole trough concentrations are not influenced by inflammation:a prospective study[J]. Int J Antimicrob Agents,2019,53(3):325-329.
VEHRESCHILD J J,MÜLLER C,FAROWSKI F,et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute mye-loid leukemia or myelodysplastic syndrome[J]. Eur J Clin Pharmacol,2012,68(6):987-995.
MICELI M H,PERISSINOTTI A J,KAUFFMAN C A,et al. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea:single centre retrospective analysis[J]. Mycoses,2015,58(7):432-436.
Research progress in pharmacokinetics and therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of gastrointestinal stromal tumors
A real-world survey of the effect of voriconazole on tacrolimus blood concentration after lung transplantation
Research progress in pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of biapenem
Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population
Multi-centre survey and analysis of individual therapy of antimicrobial agents in children
Related Author
SUN Luning
WANG Yongqing
LIU Yi
ZHAO Yang
HUANG Qiongye
LIU Lihong
CHEN Wenqian
LI Pengmei
Related Institution
Clinical Pharmacology Center, the First Affiliated Hospital of Nanjing Medical University
School of Pharmacy, Nanjing Medical University
Dept. of Pharmacy, China-Japan Friendship Hospital
Dept. of Pharmacy, the Second Hospital of Hebei Medical University
Dept. of Infectious Diseases, the Second Hospital of Hebei Medical University